Results 11 to 20 of about 2,084 (136)

Medication-related osteonecrosis of the jaw treatment modalities: A review

Journal of Craniomaxillofacial Research, 2020
Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents. Management of MRONJ has remained a controversial topic within the oral and maxillofacial surgery community ...
Amir Ali Asadi
doaj   +1 more source

Awareness, perceptions and attitudes toward medication-related osteonecrosis of the jaw among physicians who treat osteoporosis

Saudi Pharmaceutical Journal, 2023
Osteoporosis is the most common indication for antiresorptive drugs (ARDs). Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication of ARDs.
Suad Aljohani
doaj   +1 more source

Medication-related osteonecrosis of the jaw: A review about etiology, risk factors, pathophysiology, and treatment

Journal of Indian Academy of Oral Medicine and Radiology, 2020
Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse effect of antiresorptive and antiangiogenic medication. MRONJ is considered when a patient has exposed bone in the jaw for more than 8 weeks and has a history of antiresorptive and ...
Sheetal Singar, Ajay Pratap Singh Parihar, Prashanthi Reddy, Abhishek Maurya, Vishal Bamaniya   +4 more
doaj   +1 more source

Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients

Scientific Reports, 2021
Tooth extraction has been avoided since it has been considered a major risk factor for medication-related osteonecrosis of the jaw (MRONJ). However, MRONJ may also develop from tooth that is an infection source.
Sakiko Soutome, Mitsunobu Otsuru, Saki Hayashida, Maho Murata, Souichi Yanamoto, Shunsuke Sawada, Yuka Kojima, Madoka Funahara, Hiroshi Iwai, Masahiro Umeda, Toshiyuki Saito   +10 more
doaj   +1 more source

Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review

International Journal of Implant Dentistry, 2021
Background Medication-related osteonecrosis of the jaw (MRONJ), which was first reported as bisphosphonate-related osteonecrosis of the jaw (BRONJ) in bisphosphonate users, is a rare but severe soft and hard tissue disease induced by several types of ...
Mampei Kawahara, Shinichiro Kuroshima, Takashi Sawase   +2 more
doaj   +1 more source

Role of preoperative SPECT/CT standardized uptake values in medication-related osteonecrosis of the jaw: a preliminary study of SPECT/CT in relation to cone-beam CT and histopathological findings of the resected bone of mandibulectomy

The Egyptian Journal of Radiology and Nuclear Medicine, 2023
Background SPECT/CT has been applied for preoperative planning of MRONJ. Furthermore, the SUV using bone SPECT/CT has enabled quantitative analysis of jaw lesions.
Eizaburo Kobayashi, Yasuhito Tezuka, Junya Ono, Yasuo Okada, Ichiro Ogura   +4 more
doaj   +1 more source

Osteoporosis Management after the Occurrence of Medication-Related Osteonecrosis of the Jaw: A 13-Year Experience at a Tertiary Center [PDF]

Endocrinology and Metabolism
Background We investigated osteoporosis management strategies and clinical outcomes following the occurrence of medicationrelated osteonecrosis of the jaw (MRONJ).
Chun Ho Wong, Kimberly Hang Tsoi, Jingya Jane Pu, Nancy Su Jiang, Stacey Sheung Yi Chan, Connie Hong Nin Loong, Xincheng Zou, Carol Ho Yi Fong, Eunice Ka Hong Leung, Alan Chun Hong Lee, Chi Ho Lee, Kathryn Choon Beng Tan, Yu Cho Woo, Yu-xiong Su, David Tak Wai Lui   +14 more
doaj   +1 more source

Clinical values of serum Semaphorin 4D (Sema4D) in medication‑related osteonecrosis of the jaw

European Journal of Medical Research, 2023
Background Bisphosphonates (BPs) are widely used in clinical practice to prevent and treat bone metabolism-related diseases. Medication-related osteonecrosis of the jaw (MRONJ) is one of the major sequelae of BPs use. Early prediction and intervention of
Hong Mu, Ying Pang, Lili Liu, Jingbo Liu, Chunsheng Liu   +4 more
doaj   +1 more source

MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series

BMC Oral Health, 2023
Background Cancer treatment-induced bone loss (CTIBL) is the most common adverse event experienced by patients affected by breast cancer (BC) patients, without bone metastases.
Rodolfo Mauceri, Martina Coppini, Massimo Attanasio, Alberto Bedogni, Giordana Bettini, Vittorio Fusco, Amerigo Giudice, Filippo Graziani, Antonia Marcianò, Marco Nisi, Gaetano Isola, Rosalia Maria Leonardi, Giacomo Oteri, Corrado Toro, Giuseppina Campisi   +14 more
doaj   +1 more source

Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw.

PLoS ONE, 2019
Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse event of bone-modifying agents used to prevent bone complications in cancer patients with bone metastasis.
Wakako Yatsuoka, Takao Ueno, Kanako Miyano, Yasuhito Uezono, Ayame Enomoto, Miku Kaneko, Sana Ota, Tomoyoshi Soga, Masahiro Sugimoto, Toshikazu Ushijima   +9 more
doaj   +1 more source